TGFB1 and idiopathic pulmonary fibrosis: ALK5i treatment reliably improves hallmarks of fibrotic lung disease, indicating the benefits of TGFβ signaling‐directed intervention in the model and establishing ALK5i as an applicable reference compound in BLEO‐IPF mouse studies.